Announcements

Clinuvel's company releases, including archives.

Italian, Swiss expert centres report "good clinical effectiveness and good safety" of drug in rare disease prior to broader access across Europe Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that long term observational data from the use of its first-in-class drug SCENESSE® (afamelanotide 16mg) in the rare disease erythropoietic protoporphyria (EPP) have been e-published in the British Journal of Dermatology. Two expert porphyria centres – the San Gallicano Dermatological Institute in Rome and the Triemli Municipal Hospital in Zurich – have reported on the use of SCENESSE® in 115 adult EPP patients treated for up to…
Friday, 05 December 2014 12:59

Form 604 - December 5, 2014

Thursday, 04 December 2014 17:47

Appendix 3Y - December 4 2014

Thursday, 04 December 2014 17:47

Appendix 3B - December 4 2014

Thursday, 04 December 2014 10:58

Investor Update Presentation - December 2014

Friday, 28 November 2014 12:52

Results of Meeting

Friday, 28 November 2014 12:50

Chairman's Address

Friday, 28 November 2014 12:47

CEO's AGM presentation

A copy of Dr Wolgen's presentation from the 2014 AGM can be downloaded via this link.
Monday, 03 November 2014 09:36

Letter to Shareholders - November 3

3 November 2014* Dear Shareholders, The EMA’s approval of SCENESSE® (afamelanotide 16mg) on 23 October was an historic event for all stakeholders, most of all for the EPP patients who have been awaiting the therapy. The reactions from physicians and patients the past week have been overwhelming and emotive. Both groups expressed a sense of reprieve and state of euphoria; the long journey has had an impact on all. I am delighted that our teams have persisted and been able to make SCENESSE® available to all European EPP patients. I also readily admit that the conduct of the orchestra at…
Wednesday, 29 October 2014 09:26

Appendix 4C (Q1 2014-15)

Page 1 of 37

Share Price

Buy : 4.01

Sell : 4.4

First : 4.27

Last : 4.35

High : 4.35

Low : 4.2

ASX: CUV 20 mins delay.

Volume : 14,563 Trades: 21

Last Traded : 22-Dec-2014 16:10:27

Popular Articles

Investor Spotlight

Clinuvel Stock Ticker

Clinuvel Spotlight

Company History

The technology behind Clinuvel’s lead drug, SCENESSE® (afamelanotide 16mg), has been in research and development since the 1980s when a small team of scientists set out to investigate methods of preventing skin cancer in humans. Clinuvel licensed this technology and has spent over A$20million optimising the chemistry of afamelanotide (the active ingredient in SCENESSE...

Investors' Blog Posts

In 2010, Clinuvel announced that it would commence a clinical trial of a new drug for vitiligo. In late 2012 the first treatment results...

Clinuvel Non-Executive Director Brenda Shanahan has been honoured at The Australian Financial Review and Westpac Group Woman of Influence...

Since we publicly announced our vitiligo program in 2010, the entire Clinuvel team has aimed to gain a better understand this disease, its...

Related Webcasts

What can vitiligo patients do? - Lee Thomas and Dr ...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

The future of vitiligo treatment - Lee Thomas and D...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Vitiligo trials of SCENESSE® - Lee Thomas and Dr Ph...

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Quick Links